x.ilio Therapeutics

Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15.

Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com


Team Member
more about
Therese Liechtenstein
Investment Director
Latest News Entry
Xilio Therapeutics Announces Closing of Initial Public Offering

Xilio Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share

Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors

• Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic

• Two investigational new drug (IND) applications planned in 2021

Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC

Xilio Therapeutics today announced the presentation of preclinical data of its lead investigational therapies at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SICT 2020).

Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors

Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry

Xilio Therapeutics Appoints Martin H. Huber, M.D as Chief Medical Officer

To Lead XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA-4) into the Clinic while Xilio Continues to Advance its Tumor-Selective Cytokine Pipeline

all related news
all portfolio news